Wenyu Hu1, Haiyan Wei2, Keming Li3, Pei Li1, Jiamao Lin1, Rui Feng1. 1. Department of Medicine, Shandong Cancer Hospital and Institute, Ji Nan, Shan Dong, China. 2. Physical and Chemical Laboratory, Shandong Academy of Occupational Health and Occupational Medicine, Ji Nan, Shandong, China. 3. Department of Medicine science, Shandong Academy of Traditional Medicine, Ji Nan, Shandong, China.
Abstract
OBJECTIVES: Ubiquitin specific protease 32 (USP32) is a highly conserved but uncharacterized gene, which has been reported to be associated with growth of breast cancer cells. However, the role of USP32 in human small cell lung cancer (SCLC) has not been uncovered. The aim of this study was to investigate and evaluate the clinical significance of USP32 in patients with SCLC. MATERIALS AND METHODS: Expression of USP32 was firstly investigated using public online data sets and then determined in SCLC tissues and cell lines using quantitative real-time PCR, Western blotting and immunohistochemical staining. SCLC cells were transfected with a small-interfering RNA targeting USP32 mRNA and analysed for cell viability, proliferation ability, cell cycle distribution, apoptosis and invasion. RESULTS: USP32 was found to be overexpressed in SCLC tissues compared with normal tissues. High USP32 expression was significantly correlated with disease stage and invasion. In vitro experiments demonstrated that silencing of USP32 caused a significant decrease in the proliferation and migration rate of cells. Furthermore, USP32 silencing arrested cell cycle progression at G0/G1 phase via decreasing CDK4/Cyclin D1 complex and elevating p21. In addition, downregulation of USP32 significantly induced cell apoptosis by activating cleaved caspase-3 and cleaved PARP, as well as inhibiting cell invasiveness via altering epithelial mesenchymal transition expression. CONCLUSIONS: Our results suggest for the first time that USP32 is important for SCLC progression and might be a potential target for molecular therapy of SCLC.
OBJECTIVES:Ubiquitin specific protease 32 (USP32) is a highly conserved but uncharacterized gene, which has been reported to be associated with growth of breast cancer cells. However, the role of USP32 in humansmall cell lung cancer (SCLC) has not been uncovered. The aim of this study was to investigate and evaluate the clinical significance of USP32 in patients with SCLC. MATERIALS AND METHODS: Expression of USP32 was firstly investigated using public online data sets and then determined in SCLC tissues and cell lines using quantitative real-time PCR, Western blotting and immunohistochemical staining. SCLC cells were transfected with a small-interfering RNA targeting USP32 mRNA and analysed for cell viability, proliferation ability, cell cycle distribution, apoptosis and invasion. RESULTS:USP32 was found to be overexpressed in SCLC tissues compared with normal tissues. High USP32 expression was significantly correlated with disease stage and invasion. In vitro experiments demonstrated that silencing of USP32 caused a significant decrease in the proliferation and migration rate of cells. Furthermore, USP32 silencing arrested cell cycle progression at G0/G1 phase via decreasing CDK4/Cyclin D1 complex and elevating p21. In addition, downregulation of USP32 significantly induced cell apoptosis by activating cleaved caspase-3 and cleaved PARP, as well as inhibiting cell invasiveness via altering epithelial mesenchymal transition expression. CONCLUSIONS: Our results suggest for the first time that USP32 is important for SCLC progression and might be a potential target for molecular therapy of SCLC.
Authors: Shiva Akhavantabasi; Hesna B Akman; Aysegul Sapmaz; Jennifer Keller; Elizabeth M Petty; Ayse E Erson Journal: Mamm Genome Date: 2010-06-13 Impact factor: 2.957
Authors: Aysegul Sapmaz; Ilana Berlin; Erik Bos; Ruud H Wijdeven; Hans Janssen; Rebecca Konietzny; Jimmy J Akkermans; Ayse E Erson-Bensan; Roman I Koning; Benedikt M Kessler; Jacques Neefjes; Huib Ovaa Journal: Nat Commun Date: 2019-03-29 Impact factor: 14.919